Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients, throwing its hat in the ring with GlaxoSmithKline ($GSK), which is testing a rival combo therapy. Report
| Wednesday, May 27th | 1pm ET / 10am PT | Sponsored by: EMC
Scientific workflows like light-sheet microscopy and next generation sequencing are pushing research groups to develop new methods to deal with such data-intensive instrumentation. Current, mostly serialized analysis pipelines can often take days to run and often there is no 'right analysis'. Reserve Your Spot Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!